 - Patients who have been treated with any hematopoietic colony-stimulating growth factors e.g., filgrastim G-CSF, sargramostim GM-CSF 2 weeks prior to starting study drug; erythropoietin or darbepoetin therapy, if initiated at least 2 weeks prior to enrollment, may be continued 